AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Q3 2022 Earnings Call Transcript

Vincent Angotti: As we evaluate Niyad for a commercial launch, as Pam mentioned to you, it’s pretty much a top down approach from the key experts in the country that are all aware of the guidelines that they utilize. So that’s not going to require much of a sales team relative to that. That’s going to be more about education for those KEs top down. Sales force for prefilled syringes will really be limited more to contracting. Ephedrine and phenylephrine are very well known molecules. They’re used every day in surgical suites across the country. So it’s not about convincing them on the molecules themselves. They’re standards of care. It’s more about the group purchasing organizations and the integrated delivery networks, IDMs, and educating them on the availability of it through contracts moving forward.

So this will be less traditional launches that you typically seen with larger sales teams, this would be very small commercial organizations focused on a few KEs in contracting moving forward, both of which will be limited in total scope from a number standpoint when you combine them. So, we feel like it’s going to be very efficient moving forward.

Operator: This concludes our question-and-answer session. I would like to turn the conference back over to Vince Angotti for closing remarks.

Vincent Angotti: Thank you, Danielle. Thank you for joining us today and for your continued support of AcelRx. We’re excited about the progress made with our pipeline of assets, the efficiency and our cost structure, the strategic direction for DSUVIA as well as the multiple catalysts €“ potential catalysts over the next year, and we will remain focused on driving long term shareholder value. We look forward to answering any additional questions you may have offline and, again, look forward to sharing our future developments. Thank you again.

Operator: The conference has now concluded. Thank you for attending today’s presentation. You may now disconnect.